return to corporate website
Menu
Return to
www.noxopharm.com
Home
About Us
About Noxopharm
Management Team
Board of Directors
Scientific Advisors
Corporate Governance
Company Constitution
Sustainability
Noxopharm History
Research and Clinical Programs
Research and Clinical Programs
About Pharmorage
Investor Centre
Share Price
ASX Announcements
Why Invest in Noxopharm
Presentations & Interviews
Annual Reports
Financial Reports
Analyst Reports
Investor Fact Sheet
Investor FAQs
Upcoming Events
Privacy Policy
Share Registry Information
Contact Us
Contact Us
Partnering
Working at Noxopharm
Newsletter Email Alerts
ASX Announcements Email Alerts
Investor Centre
Home
>
Investor Centre
>
Why Invest in Noxopharm
Share Price
ASX Announcements
Why Invest in Noxopharm
Presentations & Interviews
Annual Reports
Financial Reports
Analyst Reports
Investor Fact Sheet
Investor FAQs
Upcoming Events
Privacy Policy
Share Registry Information
Why Invest in Noxopharm
Noxopharm:
Delivering Science. Transforming Lives.
A diverse biotechnology platform – optimising multiple drug discovery opportunities
A platform offering a revolutionary approach to therapeutics – to markets of substantial unmet medical need
Cancer & septic shock - two key focus areas of pharma M & A activity which combined are responsible for 40% (~20 million) of global deaths
Veyonda
®
has the potential to turn ‘COLD’ cancer tumours to ‘HOT’ – a highly sought outcome in the pharma industry
Lead drug candidate Veyonda
®
being developed as a potential treatment for a broad range of cancers
Run by a highly experienced management team in drug development and product commercialisation.
